Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies.

The unprecedented advances in molecular biology during the last two decades have resulted in a dramatic increase in knowledge about gene structure and function, an immense database of genetic sequence information, and an impressive set of efficient new technologies for monitoring genetic sequences, genetic variation, and global functional gene expression. These advances have led to a new sub-discipline of toxicology: “toxicogenomics”. We define toxicogenomics as “the study of the relationship between the structure and activity of the genome (the cellular complement of genes) and the adverse biological effects of exogenous agents.” This broad definition encompasses most of the variations in the current usage of this term, and in its broadest sense includes studies of the cellular products controlled by the genome (messenger RNAs, proteins, metabolites, etc.). The new “global” methods of measuring families of cellular molecules, such as RNA, proteins, and intermediary metabolites have been termed “-omic” technologies, based on their ability to characterize all, or most, members of a family of molecules in a single analysis. With these new tools, we can now obtain complete assessments of the functional activity of biochemical pathways, and of the structural genetic (sequence) differences among individuals and species, that were previously unattainable. These powerful new methods of high-throughput and multi-endpoint analysis, include gene expression arrays that will soon permit the simultaneous measurement of the expression of all human genes on a single “chip”. Likewise, there are powerful new methods for protein analysis (proteomics: the study of the complement of proteins in the cell) and for analysis of cellular small molecules (metabonomics: the study of the cellular This article has been reproduced from Mutation Research, Vol 499, 2002, pp 13–25, Aardema & MacGregor, by the permission of Elsevier Science, Ltd. metabolites formed and degraded under genetic control). This will likely be extended in the near future to other important classes of biomolecules such as lipids, carbohydrates, etc. These assays provide a general capability for global assessment of many classes of cellular molecules, providing new approaches to assessing functional cellular alterations. These new methods have already facilitated significant advances in our understanding of the molecular responses to cell and tissue damage, and of perturbations in functional cellular systems.

[1]  R G Ulrich,et al.  Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. , 2001, Toxicology letters.

[2]  J R Yates,et al.  Mass spectrometry. From genomics to proteomics. , 2000, Trends in genetics : TIG.

[3]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[4]  J. Trent,et al.  Microarrays and toxicology: The advent of toxicogenomics , 1999, Molecular carcinogenesis.

[5]  Katsushi Tokunaga,et al.  The power of genome-wide association studies of complex disease genes: statistical limitations of indirect approaches using SNP markers , 2001, Journal of Human Genetics.

[6]  F. Gilbert Disease genes and chromosomes: disease maps of the human genome. , 2000, Genetic testing.

[7]  George M. Church,et al.  Regulatory Networks Revealed by Transcriptional Profiling of Damaged Saccharomyces cerevisiae Cells: Rpn4 Links Base Excision Repair with Proteasomes , 2000, Molecular and Cellular Biology.

[8]  Jørgen K. Kanters,et al.  Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome. , 2001, Clinical chemistry.

[9]  N. Anderson,et al.  Simultaneous Measurement of Hundreds of Liver Proteins: Application in Assessment of Liver Function , 1996, Toxicologic pathology.

[10]  W. Weber Effect of pharmacogenetics on medicine , 2001, Environmental and molecular mutagenesis.

[11]  S. Gottesman,et al.  Posttranslational quality control: folding, refolding, and degrading proteins. , 1999, Science.

[12]  R. Dunn,et al.  Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  W. Kalow Contribution of hereditary factors to the response to drugs. , 1965, Federation proceedings.

[14]  W. Kalow PHARMACOGENETICS IN ANIMALS AND MAN , 1968 .

[15]  D. Nebert Drug-Metabolizing Enzymes, Polymorphisms and Interindividual Response to Environmental Toxicants , 2000, Clinical chemistry and laboratory medicine.

[16]  E Holmes,et al.  Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. , 2001, Chemical research in toxicology.

[17]  J. T. Macgregor,et al.  Strategies and testing methods for identifying mutagenic risks. , 2000, Mutation research.

[18]  W. Weber,et al.  Populations and genetic polymorphisms. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[19]  E. Sim,et al.  Arylamine N-acetyltransferases - of mice, men and microorganisms. , 2001, Trends in pharmacological sciences.

[20]  F. Kadlubar Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. , 1994, Drug metabolism reviews.

[21]  R. Dunn,et al.  Concise review: gene expression applied to toxicology. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  T. Lindahl,et al.  Quality control by DNA repair. , 1999, Science.

[23]  P. de Knijff,et al.  A powerful and rapid approach to human genome scanning using small quantities of genomic DNA. , 2001, Genetical research.

[24]  S. Cohen,et al.  The manipulation of genes. , 1975, Scientific American.

[25]  Toward construction of a transcript profile database predictive of chemical toxicity. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  T. Ørntoft,et al.  Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics , 2000, FEBS letters.

[27]  Maclyn McCarty,et al.  STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES , 1944, The Journal of experimental medicine.

[28]  William Epstein,et al.  Nuclear-Free Zones , 1975 .

[29]  S. Schreiber,et al.  Printing proteins as microarrays for high-throughput function determination. , 2000, Science.

[30]  W. Kalow Part I. Drug Metabolism Enzymes , 1968 .

[31]  Maclyn,et al.  CELEBRATING THE THIRTY-FIFTH ANNIVERSARY OF THE PUBLICATION ' OF " STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES " Induction of Transformation by a Desoxyribonucleic Acid Fraction Isolated From Pneumococcus Type III , 1998 .

[32]  E Holmes,et al.  Chemometric models for toxicity classification based on NMR spectra of biofluids. , 2000, Chemical research in toxicology.

[33]  J. Lindon,et al.  'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  R. Tennant,et al.  Transgenic animals in toxicology. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[35]  Steven J Smith,et al.  Cardiovascular Toxicity of Antihistamines , 1994, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[36]  L J Lesko,et al.  Pharmacogenomic-guided drug development: regulatory perspective , 2002, The Pharmacogenomics Journal.

[37]  J. Yates Mass spectrometry and the age of the proteome. , 1998, Journal of mass spectrometry : JMS.

[38]  A Helenius,et al.  Setting the standards: quality control in the secretory pathway. , 1999, Science.

[39]  F. Taddei,et al.  Counteraction by MutT protein of transcriptional errors caused by oxidative damage. , 1997, Science.

[40]  J. Llenas,et al.  Some observations on the cardiotoxic and drug interaction profiles of second generation antihistamines as measured in the guinea pig. , 1996, Arzneimittel-Forschung.

[41]  A. Ronen,et al.  Human DNA repair genes , 2001, Environmental and molecular mutagenesis.

[42]  F. A. Denz,et al.  Experimental methods used in determining chronic toxicity; a critical review. , 1954, Pharmacological reviews.

[43]  L. Samson,et al.  Global response of Saccharomyces cerevisiae to an alkylating agent. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Pennie Use of cDNA microarrays to probe and understand the toxicological consequences of altered gene expression. , 2000, Toxicology letters.

[45]  T. Nyström,et al.  Protein oxidation in response to increased transcriptional or translational errors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Egan,et al.  Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. , 1996, Arzneimittel-Forschung.

[47]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[48]  B. W. Penman,et al.  Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. , 1997, Advances in pharmacology.

[49]  F. Crick,et al.  Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1953, Nature.

[50]  J. Speyer,et al.  Synthetic polynucleotides and the amino acid code. , 1961, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M Pirmohamed,et al.  Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.

[52]  R. Langenbach,et al.  Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450. , 1993, Toxicology.

[53]  F. Kadlubar,et al.  Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. , 1995, Pharmacogenetics.

[54]  D J Dix,et al.  Application of DNA arrays to toxicology. , 1999, Environmental health perspectives.

[55]  J. Lederberg,et al.  `Ome Sweet `Omics--A Genealogical Treasury of Words , 2001 .